TOLREMO therapeutics

Description: TOLREMO develops resistance-breaking cancer therapies to extend patient lives, leveraging a unique drug resistance platform spun out of ETH Zurich.

Country: Switzerland

Based in: Zurich

Founded: 2017

Funding Stage: Series A/B

Tags: ['BioTech', 'MedTech', 'Drug Discovery']

Categories

Add insights to your inbox

We’ll send you content you’ll want to read- and put to use.

Details about how we process your information are available in our Privacy Policy.